ALLO — Allogene Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2018-10-11.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ALLO
| date | signal | measured base rate |
|---|---|---|
| 2026-07-30 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-16 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-08 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-27 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-21 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-18 | Kazam Joshua A Director | Option exercise | 47.7K | 0.00 | 0 |
| 2026-04-21 | Yoshiyama Annie SVP, Finance | Open-market sale | 9.6K | 2.31 | 22.1K |
| 2026-03-31 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Open-market sale | 2.9K | 2.50 | 7.2K |
| 2026-03-16 | Chang David D President and CEO | Open-market sale | 47.8K | 2.47 | 118.0K |
| 2026-03-16 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Open-market sale | 4.8K | 2.47 | 11.9K |
| 2026-03-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Open-market sale | 7.1K | 2.60 | 18.5K |
| 2026-02-02 | Chang David D President and CEO | Open-market sale | 95.3K | 1.80 | 171.5K |
| 2026-02-02 | Roberts Zachary EVP of R&D | Open-market sale | 35.7K | 1.77 | 63.2K |
| 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Open-market sale | 24.0K | 1.76 | 42.2K |
| 2026-02-02 | Douglas Earl Martin SVP, General Counsel | Open-market sale | 22.9K | 1.76 | 40.3K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Pfizer Inc | 49.8M | 22.0M |
| BlackRock, Inc. | 46.6M | 19.1M |
| TPG GP A, LLC | 45.7M | 18.7M |
| STATE STREET CORP | 21.1M | 8.7M |
| PRIMECAP MANAGEMENT CO/CA/ | 20.4M | 8.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.9M | 6.9M |
| CITADEL ADVISORS LLC | 16.6M | 6.8M |
| TWO SIGMA INVESTMENTS, LP | 13.1M | 5.4M |
| GEODE CAPITAL MANAGEMENT, LLC | 10.1M | 4.1M |
| Frazier Life Sciences Management, L.P. | 9.3M | 3.8M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Allogene Therapeutics GAAP EPS of -$0.13 beats by $0.04, revenue of $4.64M · 2026-08-12
- Allogene Therapeutics, Inc. (ALLO) filed form 8-K · 2026-08-12 · SEC EDGAR
Ask the AI about ALLO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →